Breakdown | ||||
Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
---|---|---|---|---|
Income Statement | Total Revenue | |||
3.94M | 15.53M | 13.91M | 4.36M | 0.00 | Gross Profit |
3.94M | 12.46M | 10.23M | -99.79M | -3.33M | EBIT |
-89.15M | -88.13M | -97.58M | -128.32M | -97.83M | EBITDA |
-89.15M | -85.06M | -93.91M | -124.54M | -105.06M | Net Income Common Stockholders |
-131.21M | -87.68M | -96.05M | -128.33M | -108.54M |
Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | |||
56.94M | 135.70M | 125.83M | 190.73M | 243.51M | Total Assets |
70.09M | 151.53M | 146.69M | 235.37M | 265.30M | Total Debt |
8.38M | 11.14M | 12.57M | 14.46M | 13.01M | Net Debt |
-28.62M | -124.57M | -68.77M | -172.36M | -207.38M | Total Liabilities |
99.07M | 59.45M | 42.79M | 50.64M | 45.26M | Stockholders Equity |
-28.97M | 92.08M | 103.90M | 184.73M | 220.04M |
Cash Flow | Free Cash Flow | |||
-80.87M | -79.02M | -80.33M | -116.55M | -76.33M | Operating Cash Flow |
-80.74M | -79.00M | -79.39M | -115.66M | -74.26M | Investing Cash Flow |
-18.28M | 44.98M | -26.29M | 3.02M | 32.76M | Financing Cash Flow |
355.00K | 88.33M | 164.00K | 78.68M | 192.35M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
75 Outperform | $139.54B | 292.94 | 2.28% | 2.79% | 6.16% | -91.54% | |
64 Neutral | $124.50B | ― | -3.15% | ― | 11.64% | -114.72% | |
52 Neutral | $668.27M | ― | -68.76% | ― | -65.98% | 14.00% | |
48 Neutral | $6.86B | 1.11 | -50.22% | 2.47% | 16.71% | 1.53% | |
46 Neutral | $117.76M | ― | -69.10% | ― | -9.55% | 24.57% | |
37 Underperform | $43.66M | ― | -415.84% | ― | -74.60% | ― | |
37 Underperform | $87.06M | ― | -409.51% | ― | ― | 19.70% |
On February 11, 2025, Aligos Therapeutics entered into a Securities Purchase Agreement with investors for a private placement, expected to result in approximately $105 million in gross proceeds. This funding is anticipated to support the advancement of their ALG-000184 into a Phase 2 clinical study and extend the company’s cash runway into the second half of 2026. The private placement, led by a life sciences investment firm, involves the sale of common stock and warrants and is expected to close on February 13, 2025. This financial boost is a strategic move to solidify Aligos’s position in the biotechnology industry focused on liver and viral diseases, providing potential long-term benefits for stakeholders.
On January 30, 2025, Aligos Therapeutics appointed Lesley Ann Calhoun as Chief Operating Officer while she retains her role as Chief Financial Officer. This strategic appointment aims to leverage her extensive financial and operational experience, potentially strengthening the company’s leadership and operational efficiency.